X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
daclizumab (664) 664
humans (528) 528
transplantation (328) 328
immunosuppressive agents - therapeutic use (291) 291
male (268) 268
female (259) 259
antibodies, monoclonal - therapeutic use (257) 257
index medicus (257) 257
antibodies, monoclonal, humanized (251) 251
immunology (222) 222
surgery (219) 219
adult (218) 218
immunoglobulin g - therapeutic use (218) 218
middle aged (196) 196
basiliximab (141) 141
graft rejection - prevention & control (140) 140
treatment outcome (127) 127
multiple sclerosis (126) 126
immunosuppression (117) 117
alemtuzumab (109) 109
kidney transplantation (106) 106
therapy (101) 101
drug therapy, combination (100) 100
mycophenolate-mofetil (97) 97
tacrolimus (97) 97
child (95) 95
adolescent (93) 93
recipients (92) 92
acute rejection (90) 90
immunosuppressive agents - administration & dosage (90) 90
monoclonal antibodies (89) 89
kidney transplantation - immunology (88) 88
antibodies, monoclonal - administration & dosage (85) 85
mycophenolic acid - analogs & derivatives (83) 83
immunosuppressive agents - adverse effects (80) 80
immunoglobulin g - administration & dosage (76) 76
animals (73) 73
retrospective studies (73) 73
mycophenolic acid - therapeutic use (68) 68
rituximab (68) 68
aged (67) 67
rejection (67) 67
immunotherapy (66) 66
monoclonal-antibody (66) 66
pharmacology & pharmacy (66) 66
health aspects (62) 62
graft survival (61) 61
antibodies, monoclonal - adverse effects (60) 60
time factors (60) 60
cyclosporine (59) 59
mycophenolate mofetil (59) 59
renal-transplantation (59) 59
risk factors (59) 59
receptors, interleukin-2 - antagonists & inhibitors (58) 58
tacrolimus - therapeutic use (58) 58
acute disease (57) 57
follow-up studies (57) 57
kidney-transplantation (57) 57
receptors, interleukin-2 - immunology (56) 56
calcineurin inhibitors (54) 54
clinical neurology (54) 54
immunoglobulin g - adverse effects (54) 54
induction (54) 54
natalizumab (54) 54
analysis (53) 53
double-blind (52) 52
kidneys (52) 52
pediatrics (52) 52
prospective studies (51) 51
care and treatment (50) 50
immunoglobulin g - pharmacology (50) 50
medicine & public health (50) 50
trial (50) 50
antibodies, monoclonal, humanized - therapeutic use (49) 49
cyclosporine - therapeutic use (49) 49
antithymocyte globulin (47) 47
graft rejection - epidemiology (47) 47
hematology (46) 46
graft rejection (45) 45
antilymphocyte serum - therapeutic use (44) 44
induction therapy (44) 44
renal transplantation (42) 42
antibodies, monoclonal - pharmacology (41) 41
child, preschool (41) 41
oncology (41) 41
acute cellular rejection (40) 40
immunosuppressive agents (40) 40
immunosuppressive agents - pharmacology (40) 40
multiple sclerosis - drug therapy (40) 40
graft rejection - immunology (39) 39
graft vs host disease - drug therapy (39) 39
interleukin-2 receptor (39) 39
liver transplantation (39) 39
infliximab (38) 38
prevention (38) 38
young adult (38) 38
antibody (37) 37
recombinant fusion proteins - therapeutic use (37) 37
survival (37) 37
t-lymphocytes - immunology (37) 37
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (741) 741
Spanish (24) 24
German (8) 8
French (5) 5
Polish (2) 2
Czech (1) 1
Italian (1) 1
Korean (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Multiple Sclerosis Journal, ISSN 1352-4585, 4/2019, Volume 25, Issue 5, pp. 753 - 754
We provide clinical commentary on this edition’s case report of immune-mediated encephalitis related to daclizumab therapy. 
Daclizumab | encephalitis | multiple sclerosis | NEUROSCIENCES | CLINICAL NEUROLOGY | Encephalitis
Journal Article
Transplantation, ISSN 0041-1337, 01/2000, Volume 69, Issue 2, pp. 307 - 311
Daclizumab is a monoclonal antibody directed against the alpha chain of the interleukin 2 receptor. We review our experience with the use of daclizumab in... 
daclizumab
Journal Article
American Journal of Transplantation, ISSN 1600-6135, 06/2018, Volume 18, Issue 6, pp. 1424 - 1434
Calcineurin inhibitors (CNIs, eg, tacrolimus) reduce short‐term kidney transplant failure, but chronic nephrotoxicity may contribute to late transplant loss.... 
immunosuppressant ‐ calcineurin inhibitor (CNI) | immunosuppressant ‐ fusion proteins and monoclonal antibodies: alemtuzumab | immunosuppressant ‐ mechanistic target of rapamycin (mTOR) | immunosuppression/immune modulation | clinical research/practice | kidney transplantation/nephrology | immunosuppressant ‐ fusion proteins and monoclonal antibodies: basiliximab/daclizumab | immunosuppressant - mechanistic target of rapamycin (mTOR) | immunosuppressant - calcineurin inhibitor (CNI) | immunosuppressant - fusion proteins and monoclonal antibodies: basiliximab/daclizumab | immunosuppressant - fusion proteins and monoclonal antibodies: alemtuzumab | MAMMALIAN TARGET | SURGERY | practice | EFFICACY | RAPAMYCIN INHIBITORS | kidney transplantation | immunosuppression | RECIPIENTS | TRANSPLANTATION | nephrology | EARLY CONVERSION | REQUIRING PROLONGED OBSERVATION | clinical research | KIDNEY-TRANSPLANTATION | RENAL-TRANSPLANT PATIENTS | immune modulation | immunosuppressant - fusion proteins and monoclonal antibodies: basiliximab | daclizumab | SIROLIMUS | CYCLOSPORINE | Proteins | Tacrolimus | Clinical trials | Transplantation of organs, tissues, etc | Monoclonal antibodies | Product development | Research | Kidney diseases | Health aspects | ORIGINAL ARTICLES | immunosuppressant ‐ fusion proteins and monoclonal antibodies: basiliximab | Original
Journal Article
JOURNAL OF IMMUNOLOGY, ISSN 0022-1767, 04/2016, Volume 196, Issue 7, pp. 2923 - 2931
Human NK cells can be subdivided into various subsets based on the relative expression of CD16 and CD56. In particular, CD56 bright CD16 2/dim NK cells are the... 
CANCER PATIENTS | NATURAL-KILLER-CELLS | FATIGUE SYNDROME/MYALGIC ENCEPHALOMYELITIS | CLONAL TRACKING | SYNOVIAL-FLUID | IFN-GAMMA | ARTHRITIS PATIENTS | LYMPH-NODES | IMMUNOLOGY | CEREBROSPINAL-FLUID | DACLIZUMAB TREATMENT
Journal Article
Multiple Sclerosis and Related Disorders, ISSN 2211-0348, 10/2019, Volume 35, pp. 239 - 240
Daclizumab, a monoclonal antibody directed against CD25, a subunit of the high-affinity IL-2 receptor, was licensed as a disease modifying therapy (DMT) for... 
Daclizumab | Adverse drug reaction
Journal Article
ANNALS OF SURGERY, ISSN 0003-4932, 04/2005, Volume 241, Issue 4, pp. 607 - 613
Sum. Background Data: The intestine has been more difficult to transplant than other solid organs. We analyzed registry data to determine the scope and success... 
MORTALITY | SURGERY | SMALL-BOWEL TRANSPLANTATION | PEDIATRIC RECIPIENTS | EFFICACY | DACLIZUMAB | PARENTERAL-NUTRITION | EXPERIENCE | QUALITY-OF-LIFE | COMBINED LIVER | CHILDREN
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2015, Volume 112, Issue 42, pp. 13045 - 13050
Despite significant advances in the treatment of Hodgkin’s lymphoma (HL), a significant proportion of patients will not respond or will subsequently relapse.... 
Biological Sciences | radioimmunotherapy | 90Y-daclizumab | myelodysplastic syndrome | Hodgkin's lymphoma
Journal Article
Transplant International, ISSN 0934-0874, 01/2000, Volume 13, Issue 2, pp. 151 - 159
Daclizumab is a genetically engineered human IgG1 monoclonal antibody specific for the chain of the IL-2 receptor. A pooled analysis of two randomized,... 
Daclizumab
Journal Article
American Journal of Transplantation, ISSN 1600-6135, 01/2017, Volume 17, Issue 1, pp. 22 - 27
Journal Article
Clinical kidney journal, ISSN 2048-8505, 08/2019, Volume 12, Issue 4, pp. 592 - 599
Interleukin-2 (IL-2) antagonist has been used as an induction therapy in many centres in calcineurin inhibitor-sparing regimens. Tacrolimus has overwhelmingly... 
Journal Article
American Journal of Transplantation, ISSN 1600-6135, 04/2019, Volume 19, Issue 4, pp. 1150 - 1159
Journal Article
TRANSFUSION, ISSN 0041-1132, 12/2018, Volume 58, Issue 12, pp. 2924 - 2932
BACKGROUND: CD56(bright) natural killer (NK) regulatory cells were recently shown to display a differential impact on the risk of developing extensive chronic... 
ACTIVATION | NK CELLS | PHOTOCHEMOTHERAPY | IN-VIVO | REGULATORY T-CELLS | DACLIZUMAB | POPULATIONS | HEMATOLOGY | STEROID-REFRACTORY ACUTE | CLINICAL-RESPONSE | BLOOD
Journal Article
Clinical Immunology, ISSN 1521-6616, 2014, Volume 155, Issue 2, pp. 176 - 187
Abstract Interleukin-2 receptor α chain (CD25) is overexpressed in human T-cell leukemia virus 1 associated adult T-cell leukemia/lymphoma (ATL). Daclizumab a... 
Allergy and Immunology | Daclizumab | Adult T-cell leukemia/lymphoma | Monoclonal antibody | Human T-cell leukemia virus 1 (HTLV-1) associated ATL | Interleukin-2 receptor alpha | LEUKEMIA-LYMPHOMA | INTERLEUKIN-2-RECEPTOR | PROLIFERATION | INDUCTION | IMMUNOLOGY | HUMANIZED ANTI-TAC | THERAPY | REJECTION | AND/OR PARACRINE GROWTH | IL-2 RECEPTOR | BLOCKADE | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Interleukin-2 Receptor alpha Subunit - antagonists & inhibitors | Humans | Leukemia-Lymphoma, Adult T-Cell - mortality | Middle Aged | Immunoglobulin G - therapeutic use | Immunophenotyping | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Immunoglobulin G - adverse effects | Young Adult | Leukemia-Lymphoma, Adult T-Cell - drug therapy | Interleukin-2 Receptor alpha Subunit - metabolism | Antineoplastic Agents - adverse effects | Leukemia-Lymphoma, Adult T-Cell - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Adolescent | Immunoglobulin G - pharmacology | Adult | Female | Aged | Antineoplastic Agents - pharmacology | Care and treatment | Multiple sclerosis | Lymphomas | T cells | Leukemia | interleukin-2 receptor-alpha | Adult T-cell leukemia | monoclonal antibody | daclizumab, human T- cell leukemia virus 1 (HTLV-1) associated ATL | lymphoma
Journal Article
JOURNAL OF IMMUNOLOGY, ISSN 0022-1767, 07/2011, Volume 187, Issue 2, pp. 781 - 790
Functional NK cell deficiencies are associated with autoimmune diseases, including multiple sclerosis. NK cells can promote or inhibit adaptive immunity via... 
NATURAL-KILLER-CELLS | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | DIFFERENTIAL EXPRESSION | LYMPH-NODES | REGULATORY T-CELLS | DACLIZUMAB | PERFORIN | CENTRAL-NERVOUS-SYSTEM | PERIPHERAL-BLOOD | INTERFERON-BETA | IMMUNOLOGY
Journal Article
The American journal of managed care, ISSN 1088-0224, 2013, Volume 19, Issue 2, pp. S15 - S20
Multiple sclerosis.(MS) is a chronic inflammatory demyelinating disease of the central nervous system that affects approximately 400,000 people in the United... 
CRITERIA | CELLS | MEDICINE, GENERAL & INTERNAL | THERAPY | HEALTH CARE SCIENCES & SERVICES | DACLIZUMAB | DISABILITY | HEALTH POLICY & SERVICES | LESIONS | Multiple Sclerosis - physiopathology | Multiple Sclerosis - diagnosis | United States | Humans | Female | Male | Multiple Sclerosis - epidemiology | Disease Progression
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.